Table 1.
Baseline patient, disease, and transplant characteristics
| ATG group (n = 251) | Non-ATG group (n = 473) | P | |
|---|---|---|---|
| Follow-up, median (IQR), mo | 58.1 (24.0-83.3) | 58.9 (31.6-83.5) | |
| Patient age at allo-HCT, median (range), y | 39 (18.1-67.7) | 39.6 (18.1-62.1) | .34 |
| Patient sex | |||
| Male | 141 (56.18) | 251 (53.07) | .42 |
| Female | 110 (43.82) | 222 (46.93) | |
| Disease status at allo-HCT | |||
| CR1 | 164 (65.34) | 325 (68.71) | .65 |
| CR2+ | 55 (21.91) | 93 (19.66) | |
| Advanced | 32 (12.75) | 55 (11.63) | |
| Cytogenetics risk category* | |||
| Good | 45 (17.93) | 90 (19.03) | .66 |
| Intermediate | 134 (53.39) | 262 (55.39) | |
| Poor | 72 (28.68) | 121 (25.58) | |
| FLT3-ITD | |||
| Negative | 64 (58.18) | 132 (59.46) | .82 |
| Positive | 46 (41.82) | 90 (40.54) | |
| Missing | 141 | 251 | |
| NPM1 mutation | |||
| Negative | 57 (65.52) | 102 (62.58) | .65 |
| Positive | 30 (34.48) | 61 (37.42) | |
| Missing | 164 | 310 | |
| KPS at allo-HCT | |||
| <90% | 47 (19.75) | 97 (21.85) | .52 |
| ≥90% | 191 (80.25) | 347 (78.15) | |
| Missing | 13 | 29 | |
| Graft source | |||
| BM | 43 (17.13) | 102 (21.56) | .16 |
| PB | 208 (82.87) | 371 (78.44) | |
| Donor type | |||
| MSD | 27 (10.76) | 385 (81.4) | <.01 |
| UD 10/10 | 164 (65.34) | 72 (15.22) | |
| UD 9/10 | 60 (23.90) | 16 (3.38) | |
| Locus mismatch in UD 9/10 | |||
| A | 16 (26.7) | 5 (31.25) | |
| B | 8 (13.3) | 4 (25.00) | |
| C | 19 (31.7) | 4 (25.00) | |
| DR | 5 (8.30) | 2 (12.50) | |
| DQ | 12 (20.0) | 1 (6.25) | |
| Female donor/male recipient | |||
| No | 209 (83.6) | 369 (78.01) | .07 |
| Yes | 41 (16.4) | 104 (21.99) | |
| Missing | 1 | 0 | |
| Patient CMV serology | |||
| Negative | 87 (34.94) | 191 (41.34) | .10 |
| Positive | 162 (65.06) | 271 (58.66) | |
| Missing | 2 | 11 | |
| Donor CMV serology | |||
| Negative | 142 (56.57) | 224 (48.7) | .05 |
| Positive | 109 (43.43) | 236 (51.3) | |
| Missing | 0 | 13 | |
| HCT-CI at allo-HCT | |||
| <3 | 72 (77.42) | 150 (85.71) | .09 |
| ≥3 | 21 (22.58) | 25 (14.29) | |
| Missing | 158 | 298 | |
| Conditioning regimen | |||
| Cy-TBI | 212 (84.46) | 442 (93.45) | <.001 |
| Flu-TBI | 39 (15.54) | 31 (6.55) | |
| Associated IST | |||
| CSA | 7 (2.79) | 12 (2.54) | .12 |
| CSA + MTX | 182 (72.51) | 351 (74.21) | |
| CSA + MMF ± MTX | 35 (13.94) | 42 (8.88) | |
| TACRO ± other | 18 (7.17) | 54 (11.41) | |
| Other | 9 (3.59) | 14 (2.96) | |
| Type of DLI | |||
| No DLI | 227 (90.8) | 443 (93.66) | .31 |
| Preemptive | 7 (2.8) | 7 (1.48) | |
| After relapse | 16 (6.4) | 23 (4.86) | |
| Missing | 1 | 0 | |
| Graft failure | |||
| Graft failure | 3 (1.2) | 5 (1.06) | 1.0 |
| Missing | 2 | 3 |
Unless otherwise noted, data are n (%). Percentages do not include “missing” data.
CR1, first complete remission; CR2+, second or later complete remission; CSA, cyclosporin; Cy, cyclophosphamide; DLI, donor lymphocyte infusion; Flu, fludarabine; HCT-CI, hematopoietic cell transplantation–comorbidity index; IQR, interquartile range; IST, immunosuppressive therapy; KPS, Karnofsky performance status; MMF, mycophenolate mofetil; MSD, matched sibling donor; MTX, methotrexate; TACRO, tacrolimus; UD, unrelated donor; ±, with or without.
*
Based on European Leukemia Net risk stratification.24